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Abstract The ability of the alternative pathway of complement 
to discriminate targets as either activators or non-activators is 
mediated by different binding properties of factor H to surface- 
associated C3b molecules. In the present study we have probed 
the interaction between H and C3b using five anti-H mAb. The 
binding sites of the mAb were mapped by Western blotting using 
both recombinant and trypsin-generated H fragments. Two mAb 
bound to CCP1 (90X, 196X), two to CCP5 (MRC OX24, 86X) 
and one to CCP8-15a (13IX). At a molar ratio 2:1 of 12si- 
l l  :mAb all tested mAb enhanced binding of H to both activator- 
and non-activator-bound C3b. At higher concentrations two mAb 
had an inhibitory effect on H binding to surface-associated C3b 
(OX24, 131X). Thus the mAb 131X inhibits H binding to 
surface-bound C3b but unlike OX24 it does not bind to the 
previously described C3b binding site within or near CCP4-5. 
These results indicate that there is an additional interaction site 
on factor H for surface-bound C3b. 
Key words: Complement factor H; Complement pathway, 
Alternative; Complement activation; Dextran sulfate; 
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I. Introduction 
The alternative pathway (AP) of complement (C) acts as a 
first line defence mechanism against a wide range of targets 
[1]. Initiation of its activation is not based on any specific 
target-associated factor. Instead, the AP is continuously acti- 
vated at a low rate in human plasma by spontaneous hydro- 
lysis of C3 molecules [2,3]. AP activation is limited by regu- 
latory proteins in the fluid phase and on non-activator 
surfaces but not on activating foreign targets ('activators') 
[4-6]. 
Factor H (H) acts as a crucial fluid phase regulator of the 
AP by inhibiting the formation and activity of C3-convertases 
[7,8]. H is also capable of discriminating between AP activa- 
tor- and non-activator-bound C3b molecules on surfaces [9- 
12]. High affinity of H to target-associated C3b restricts for- 
mation of the AP C3-convertase by preventing the binding of 
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factor B to C3b and by supporting dissociation of C3bBb and 
rapid cleavage of C3b by factor I [7,8,13,14]. High affinity of 
H to C3b is favored by cell surface components present on AP 
'non-activators', e.g. by sialic acid residues on glycophorin A
and glycosaminoglycans [ 10-12,14,15], and leads to down-reg- 
ulation of complement activation. C3b on 'activators', i.e. on 
surfaces which lack the protecting surface elements, has a 
relatively low affinity for H. Thereby the surface-bound C3b 
molecules escape the AP regulatory control. 
Because of the important role of H in discriminating be- 
tween host and non-host structures, the binding sites and 
mechanisms of interaction between H and C3b on different 
surfaces are of great interest. Factor H is an elongated 150 
kDa glycoprotein composed of 20 complement control protein 
domains (CCP) [16]. The main interaction site of H for C3b 
has been located within or near CCP4~5 in the N-terminal 34 
kDa tryptic fragment [17,18]. Factor H also has a binding site 
for polyanions ('heparin binding site') in CCP12 15 [19], 
which has been proposed to be an important site for recogni- 
tion of non-activators. The interaction of H with C3b appears 
to involve at least two regions in C3b spanning residues 1187- 
1249 [20] and 727-768 [21] but whether two or more recipro- 
cal regions on H exist has not yet been examined. 
To analyze the binding of H to activator- and non-activa- 
tor-bound C3b we have tested the effects of a set of anti-H 
mAb on the interaction. Our specific goals in this study were 
to map the binding sites of four previously uncharacterized 
anti-H mAb, and to examine how the binding of five mAb to 
different sites on H affects the interaction between H and C3b. 
Our results provide the first evidence that binding of H to C3b 
is not restricted to one site on H. Multiple interactions be- 
tween C3b and H may play an important role during target 
recognition by the AP. 
2. Materials and methods 
2.1. Reagents and cells 
Trypsin (type I from bovine pancreas), heparin (average m 11 000 
Da), soybean trypsin-chymotrypsin inhibitor (SBTI) and zymosan (Z) 
were obtained from Sigma Chemical Co. (St. Louis, MO). Na12'~l was 
obtained from Amersham International plc (Amersham, UK). For 
working solutions the reagents and cells were dissolved into vero- 
nal-buffered saline (VBS: 3.2 mM barbituric acid, 1.8 mM sodium 
barbital and 146 mM NaCI; pH 7.35), GVB (0.1% gelatin in VBS) 
or BVB (0.1% BSA in VBS). Zymosan was used in assays after boiling 
(10 min) in VBS. 
All rights reserved. 
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2.2. Antibodies 
BALB/C mice were immunized intraperitoneally with highly puri- 
fied human factor H on two occasions. 4 days after the second im- 
munization, a mouse was splenectomized and the splenocytes were 
fused with the X63 Ag8 HAT-sensitive cell line using a modification 
of the method of K6hler and Milstein [22]. Supernatants from the 
resultant clones were tested for antibody to factor H and antibody- 
positive hybridomas were subcloned. Thereafter supernatant from 
each clone was again tested by EIA on factor H, C3, C5, and factor 
B. Only factor H-positive clones were identified. Four of these mouse 
hybridoma cell lines producing IgG anti-H antibodies (86X, 90X, 
131X and 196X) were grown in RPMI 1640 (Gibco Laboratories, 
Paisley, UK) supplemented with L-glutamine (2 mM; NordCell, 
Bromma, Sweden), penicillin (10 IU/ml), streptomycin (100 ~tg/ml) 
and 10% lgG-free heat-inactivated FCS (Gibco BRL, Gaithersburg, 
MD). Antibodies were purified from hybridoma supernatants by pro- 
tein G affinity chromatography (Pharmacia, Uppsala, Sweden). Three 
mAb (86X, 90X, 196X) were found to be of the IgG1 subclass and one 
mAb (131X) of the IgG2b subclass. MRC OX24 (OX24) antibody 
(mouse lgGl)[23] was a kind gift of Prof. R.B. Sire (University of 
Oxford, UK). 
2.3. Complement components 
C3 and factors B, D and H were purified from human plasma using 
methods previously described [11,12,24,25]. Purity of these proteins 
was examined by SDS-PAGE and was found to be > 90%. Factor 
H and C3 were radiolabeled with Na12sI using the lodogen method 
(Pierce Chemical Corp., Rockford, IL). Protein-bound radioactivity 
was separated from free 125I by using Sephadex G-25 columns (Phar- 
macia). The initial specific activities of 1251-labeled H and C3 ranged 
from 0.16 to 1.25× 10 G cpm//ag and from 2.2 to 4.4× 106 cpm/lag, 
respectively. Limited fragmentation of H with trypsin was performed 
as described earlier [19], using 750 p.g/ml factor H, 1.5% (w/w) trypsin, 
55 gg/ml heparin and 3% (per weight of H) soybean trypsin-chymo- 
trypsin inhibitor. Cleavage patterns were analyzed by SDS-PAGE. 
2.4. Recombinant H jragments 
Cloning, expression and purification of the various recombinant 
proteins have been described elsewhere [29]. Briefly, specific primers 
were used to amplify fragments containing various CCP domains 
using the human factor H cDNA as a template. Amplified tYagmcnts 
were cloned into the baculovirus transfer vector pBSV-SHis. Recom- 
binant virus was generated and isolated by standard techniques and 
used to infect Spodoptera frugiperda cells (Sf9). For recombinant ex- 
pression Sf9 cells were grown in FCS-free Express medium (BioWhit- 
taker) and the recombinant proteins were purified by Ni2--NTA agar- 
ose chromatography [30,31], 120 h after infection. Purity of the 
recombinant fragments was examined by SDS-PAGE and found to 
be > 95%. 
2.5. SDS-PAGE and immunoblotting 
SDS-PAGE was performed according to Laemmli [32], using 8 or 
10 15% gradient gels and either reducing (tryptic H fragmentst or 
non-reducing (recombinant H fragments) conditions. Gels were either 
stained with Coomassie Brilliant Blue R-250 (Serva Feinbiochemica 
GmbH, Heidelberg, Germany), silver-stained or used for immunoblot- 
ting. For immunoblotting the peptides were transferred from SDS- 
PAGE gel to a nitrocellulose sheet (0.45 gm; Schleicher and Schuell, 
Dassel, Germany) [33], which was subsequently blocked with 3 or 5% 
(w/v) BSA in PBS. Antibodies diluted in 3% BSA-PBS were used at 
10 20 ~tg/ml (17 h at +22°C). After washes (3×10 min) alkaline 
phosphatase-conjugated rabbit anti-mouse IgG (Zymed Laboratories, 
San Francisco, CA or Jackson ImmunoResearch Laboratories Inc., 
West Grove, PA) was used as a secondary antibody (1:1000 dilution, 
60 rain at 37°C or 2 h at 22°C). After three washes the immunoblot 
was incubated for 5 15 min at 22°C with a substrate solution contain- 
ing nitroblue tetrazolium (Sigma) and 5-bromo-4-chloro-3-indolyl 
phosphate (Boehringer Mannheim GmbH, Mannheim, Germany) 
each dissolved in dimethyl formamide (Merck, Darmstadt, Germany) 
and finally diluted into 0.1 M NaHCO:~ buffer (pH 9.7) containing 
1 mM MgCI2. 
2.6. Factor H binding assays 
C3b was coupled to SRBC or zymosan by using the AP C3-con- 
vertase amplification method [26,27]. The number of C3b bound to 
cells during coupling was measured by using 1251-C3 in a simultaneous 
and analogous coupling procedure. The number of C3b molecules 
ranged between 1400 9700/cell on SRBC and 115000 176000/cell 
on Z. Binding of 1251-H to Z-C3b or SRBC-C3b was analyzed as 
described previously [11,12]. To study the effects of mAb on H bind- 
ing, the mAb were equilibrated (5 min, 22°C) with 1251-H prior to 
addition of cells. To separate cell-bound and free radioactive proteins 
the mixtures were rapidly centrifuged through 20'7,, sucrose as de- 
scribed previously [28]. Radioactivity in both pellets and supernatants 
was counted. GVB or BVB was used as buffer and all assays were 
performed in duplicate. 
2. 7. Radioimmunoassay procedures 
Radioimmunoassay (RIA) was performed using Polysorp plates 
(Nunc, Denmark) with removable wells. Wells were coated with 80 
gl of H or BSA at 10 gg/ml in VBS (17 h, 22°C). After removing 
unbound protein, wells were washed and incubated with 200 gl BVB- 
T (0.1% BSA, 0.1% Tween 20; 15 min, 22°C) to prevent non-specific 
binding. Wells were washed three times with VBS-T (0.1% Tween 20), 
followed by addition of anti-H mAb at various dilutions and 12"~I-H 
(~ 30 000 cpm) in 1/3 BVB-T. After incubation (60 min, 30 or 37°C) 
the unbound proteins were removed and wells were washed four times 
with 1/3 BVB-T. Wells were counted separately and all assays were 
performed in duplicate. 
3. Results 
3.1. Mapping o f  mAb binding sites on f iwtor H 
The binding sites o f  five ant i -H mAb on H were mapped by 
Western blott ing using both  recombinant  and tryptic frag- 
ments  o f  H. Recombinant  f ragments  contain ing CCP units 
1, I 2, 1 3, 14 ,  1 5, 1 6, 1 7 ,2  6, 13 and 19-20 were used 
(Fig. la). 90X and 196X mAb bound to all f ragments  contain-  
ing CCP1, but not  to the f ragment  contain ing CCP2-6 .  How-  
ever, 196X bound most  clearly to f ragments CCP1 6 and 1-7. 
In addit ion,  weak binding of  196X was seen to other frag- 
ments  contain ing CCP1. OX24 and 86X bound to CCP1-7 ,  1 
6, 1 5 and 2-6 but not  to the other f ragments tested. 131X did 
not  b ind to any of  the recombinant  f ragments tested (Fig. 1). 
None  of  the tested mAb bound to f ragments contain ing 
Fig. 1. Binding sites of five anti-factor H mAb. (a) Western blotting of recombinant H fragments with various anti-H mAb. Fragments (0.5 
gg) were either separated by SDS-PAGE (10 15% gradient gels) under non-reducing conditions and electrotransferred to nitrocellulose sheets 
(86X, OX24 and 131X) or dot-blotted irectly on nitrocellulose membranes (90X and 196X). Molecular weight standards are shown on the 
left, and numbers of CCPs in each recombinant fragment are shown on top of each lane or dot. (b) Western blotting of trypsinized H with 
various anti-H mAb. Factor H (750 gg/ml) was treated for 1 or 20 min with trypsin (1.5% w/w) in the presence or absence of heparin (55 gg/ 
ml). Lanes: 1, native factor H; 2, 20 rain treatment with trypsin in the absence of heparin; 3, 1 rain treatment with trypsin in the presence of 
heparin; 4, 20 min treatment with trypsin in the presence of heparin. Samples were run in SDS-PAGE under reducing conditions and trans- 
ferred to nitrocellulose sheets. Molecular weight standards are shown on the left and the molecular weights of distinct fragments of H are 
shown on the right. (c) A schematic diagram of trypsin fragments of factor H. Identity of the fragments obtained in the presence or absence of 
heparin, is based on chromatographic separation and N-terminal sequence analysis of the fragments [19]. Asterisk denotes previously uncharac- 
terized trypsin fragment whose identity was deduced from its molecular weight and binding patterns of characterized mAb. (d) The deduced 
binding sites of the mAb used depicted on the elongated factor H molecule composed of 20 repeating CCP units. N-terminus is to the left. De- 
duced binding sites of the mAb were obtained from data in (a) and (b). 
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Fig. 2. Binding of 12:'I-H to C3b-coated zymosan (@) or plain zymo- 
san (©) in the presence of increasing amounts of anti-H mAb. Var- 
ious mAb were incubated with tz~I-H (5 min at 22°C) in GVB or 
BVB before the zymosan particles ((~12×106 particles/80 ~al; 
115 000-175000 C3b molecules/particle) were added and the mixture 
incubated for 30 min at 37°C. Cell-bound radioactivity was deter- 
mined after rapid centrifugation of cells through 20% sucrose. 
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Fig. 3. The effect of increasing amounts of anti-H mAb on binding 
of m:q-H to C3b-coated SRBC (I) or plain SRBC (©). The mAb 
and 1251-H were preincubated together (5 min at 22°C), mixed with 
SRBC-C3b (3.3× 107 cells/80 ILl; 1400-9700 C3b molecules/cell) and 
incubated for 30 min at 37°C. Cell-bound radioactivity was deter- 
mined after centrifugation through 20% sucrose. 
CCP13 or CCP19-20 (data not shown). For mapping of the 
binding site of the 131X mAb well characterized tryptic H 
fragments were obtained as previously described [19]. The 
binding site was determined using a Western blot of H frag- 
ments separated under reducing conditions (Fig. lb) and the 
previously published digestion pattern elucidated by N-termi- 
nal amino acid sequencing (Fig. lc)[19]. The 131X mAb 
bound to the 127, 117 and 82 kDa tryptic fragments, and 
weakly to a previously undescribed 132 kDa fragment. 86X, 
90X, 196X and OX24 bound to the N-terminal 34 kDa frag- 
ment as expected (only 86X and OX24 are shown in Fig. 1; 
the binding site of OX24 is the same as previously shown 
[34]). 86X bound also to the 132 kDa fragment, but not to 
the 127 kDa tryptic fragment. A summary of the mAb site 
analysis is shown in Fig. ld. 
3.2. Effects o f  mAb on H binding to Z-C3b 
Five monoclonal anti-H antibodies (86X, 90X, 131X, 196X, 
OX24) were tested for their effects on H binding to surface 
associated C3b. At low concentrations (0.12 1.2 lag/ml) all the 
tested mAb showed an enhancing effect on H binding to Z- 
C3b (Fig. 2). The magnitude of the effect ranged from 1.6-fold 
(86X: 7.8 vs 5.0%) to 2.7-fold (90X: 12.9 vs 4.8%). The en- 
hancing effect was no longer seen at higher concentrations (3- 
11 lag/ml), whereas at the highest concentrations (10 300 lag/ 
ml) the effects of the mAb fell into three different categories: 
(1) two mAb (86X, 90X) showed an enhancing effect (Fig. 
2a,b); (2) one mAb (196X) had no effect (Fig. 2c); and (3) 
two mAb (131X and OX24) inhibited binding of H to Z-C3b 
(Fig. 2d,e). The secondary enhancing effect varied from a 50% 
(86X) to a 116% (90X) increase as compared to the nadir. The 
maximum inhibitory effect varied from 55% (131X: 6.5 vs 
2.9'7,1) to 72% (OX24:7.1 vs 2.0%) when compared to the 
basal level of H binding. Binding of H to plain Z in the 
presence of different mAb ranged from 0.4 to 2.0% of offered 
m~I-H corresponding to 9-30% of 12'5I-H bound to Z-C3b at 
the same mAb concentrations. The concentration of the mAb 
¢-~ 6000"  o ~ ~31X 
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1~ 2000 
"0 
C 
o = 
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o 1 1 o 1 oo 1 ooo  
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Fig. 4. Radioimmunoassay (RIA) analysis of the ability of mAb to 
cross-link solid-phase H and fluid-phase m~I-H. After coating plastic 
plate wells with H or BSA, non-specific binding sites were blocked 
with 0.1"/,, BSA. 125I-H and increasing amounts of OX24 ([]), 131X 
(©) or 86X mAb (zx) were incubated in wells (60 rain, 30 or 37°C) 
and the bound radioactivity was determined after four washes. 
Binding of i2~I-H to BSA coated wells was below 410 cpm/well. 
T.S. Jokiranta et al./FEBS Letters 393 (1996) 297 302 301 
did not significantly affect non-specific binding of H to Z (Fig. 
2c). 
3.3. Effects of  mAb on H binding to SRBC-bound C3b 
Binding of 125I-H to SRBC and SRBC-C3b was examined 
in the presence of varying amounts of the anti-H mAb. On the 
basis of their different binding sites on H or different effects 
on H binding to Z-C3b three mAb (OX24, 86X and 131X) 
were chosen for the analysis. All three mAb showed a similar 
enhancing effect on H binding to SRBC-C3b as to Z-C3b at 
low mAb concentrations (Fig. 3), although the effect was 
smaller when using Z-C3b (Fig. 2). Also, at higher mAb con- 
centrations the enhancing effect of 86X and the inhibitory 
effect of OX24 and 131X on H binding to SRBC-C3b were 
equivalent to that seen with Z-C3b. Binding of 125I-H to plain 
SRBC was below 0.41% of total 12~I-H offered, compared 
with 10-20°/,, binding to SRBC-C3b. 
3.4. Cross-linking of  H molecules by mAb 
The ability of the different mAb (131X, OX24 and 86X) to 
form cross-linked imers of H was examined by a sandwich- 
type radioimmunoassay using plates coated with H. Both 
131X and 86X were found to link soluble 125I-H to solid 
phase H in a dose-dependent manner (Fig. 4). A similar but 
somewhat weaker effect was seen with OX24. With each of the 
mAb an equilibrium peak effect was reached at a concentra- 
tion of 1.7 ~tg/ml which corresponds to a molar ratio of 1 : 1.2 
between the mAb and 125I-H. At concentrations above 50 ~tg/ 
ml only 86X had a weak secondary enhancing effect on H 
binding. This finding is compatible with results from experi- 
ments measuring H binding to cell-bound C3b. 
4. Discussion 
The special emphasis of the present study was to find out 
how different anti-H mAb affect the interaction between H 
and C3b - the key recognition event of the alternative com- 
plement pathway. The main observation was that mAb bind- 
ing either to the N-terminal CCP5 domain (OX24) or middle 
region CCP8-15a (131X) of factor H were capable of inhibit- 
ing the binding of H to SRBC- and Z-associated C3b. This 
data suggests that the interaction between C3b and factor H is 
not restricted to one site only. 
All tested mAb enhanced H binding to C3b-coated Z (Fig. 
2) and SRBC (Fig. 3) at molar ratios of mAb to H ranging 
from 1 : 1.5 to 1:2.9. The sandwich RIAs verified that the mAb 
can crosslink two H molecules (Fig. 4). Thus, it is apparent 
that the low concentration enhancement effect, i.e. the in- 
creased avidity of H to surface-bound C3b, is explained by 
the ability of the antibodies to bind simultaneously to two 
distinct H molecules. 
At mAb concentrations above 10 I.tg/ml two kinds of mAb 
effects on H binding, enhancing or inhibitory, were seen. 86X 
and 90X showed a second enhancing effect on H binding. The 
mechanism of this second peak of enhancement is not appar- 
ent, but could be explained e.g. by further cross-linking of H 
molecules by mAb binding to secondary low-affinity binding 
sites on H under conditions where the high-affinity binding 
sites are fully occupied. Because of structural similarity be- 
tween the individual CCP domains it is possible that a single 
mAb can bind to more than one site on factor H. Interest- 
ingly, 196X mAb binds to CCP1 and not to CCP2-6 but the 
presence of CCP6 in addition to CCPI clearly enhances the 
binding. It has previously been suggested that the N-terminal 
domains of H (CCP1-5) form a loop-like structure [34]. This 
model could explain the curious binding properties of 196X. 
Among the mAb which bind to the N-terminal 34 kDa 
fragment of H (90X, 196X, 86X and OX24) OX24 was the 
only mAb inhibiting H binding to surface-bound C3b at high- 
er mAb concentrations (> 10 ~ag/ml). This mAb has pre- 
viously been shown to bind to the region CCP4-5 [34] and 
to block H binding to RBC-bound C3b [23]. In the present 
study we found that OX24 binds to CCP5. We also found that 
OX24 inhibits H binding to Z-C3b at lower mAb concentra- 
tions than to SRBC-C3b (50% inhibition at ~ 14 vs > 125 p.g/ 
ml, respectively). Thus, it seems that either OX24 disturbs the 
binding site on H CCP4~5 for SRBC-C3b less than for Z-C3b 
or that on SRBC-bound C3b there is another binding site of 
H for C3b. Interestingly, another CCP5-binding mAb 86X did 
not inhibit H binding to surface-bound C3b. This may indi- 
cate that 86X mAb binds to an opposing face of the CCP5 
domain. 
The 131X mAb was found to bind to the middle part of H. 
It bound to a 82 kDa tryptic fragment (CCP6b 15a), but not 
to recombinant fragments of CCP1-7 or 13. The fact that 
131X did not bind to a 66 kDa tryptic fragment derived 
from the 82 kDa fragment suggests that the epitope may be 
located within the 16 kDa fragment spanning the region 
CCP13b-15a. As binding to CCP13 was excluded by recom- 
binant fragments, 131X probably binds to CCP14-15a. Inter- 
estingly, although 131X binds to the middle part of H it in- 
hibits H binding to ZC3b and SRBC-C3b. 
The mapping of mAb binding sites on H was performed by 
Western blotting and dot-blotting using both recombinant 
and tryptic fragments of H. It was found that all the mAb 
bound to H under both reducing and non-reducing condi- 
tions. The mapping with the recombinant fragments was per- 
formed under both reducing and non-reducing conditions 
after either transfer of fragments from an SDS-PAGE gel or 
direct dot-blotting on a nitrocellulose sheet. The data from all 
these blottings was consistent, i.e. the binding sites of the four 
mAb which bound to the recombinant fragments eemed 
mainly to be conformation i dependent and on the CCPI 7 
there did not seem to be any additional conformation-depend- 
ent binding sites (only analysis under non-reducing conditions 
is shown in Fig. 1). In contrast, the mapping with tryptic 
fragments was performed under reducing conditions. The re- 
duction was necessary to separate the trypsin-generated frag- 
ments from each other, but it also caused enaturation f the 
generated fragments and thus only the conformation-inde- 
pendent binding sites were explored. However, many antibod- 
ies can bind to conformational epitopes which are destroyed 
under reducing conditions and such epitopes on the CCP8 20 
could not be detected by the mapping methods used. 
Two main observations ow suggest that there are at least 
two distinct sites on H important for its binding to surface- 
bound C3b: (1) despite mAb-induced blocking of a specific 
site on H during the enhancing effect (e.g. with OX24), the 
molecule still can interact with surface-associated C3b mole- 
cules, and (2) 131X mAb inhibits H binding although it binds 
to CCP8-15a far from the binding site for C3b within or near 
CCP4~5. In the two-binding-site model the N-terminal (within 
or near CCP4-5) binding site is affected by OX24 and the 
second binding site in the middle of H (CCP8 15a) is affected 
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by 131X. It is not yet known whether the second binding site 
interacts directly with C3b, non-activator-surface or jointly 
with both. However, we cannot exclude allosteric effects of 
the 131X mAb, i.e. binding of the mAb to one site could 
induce a thermodynamically stable conformational change at 
a functionally more important distant site, e.g. at CCP4 5. 
Several results of earlier studies can be explained by the 
existence of two interaction sites between H and SRBC-C3b, 
e.g. the effects of polyanions [12,35,36] or various trypsin 
treatments of H [17,37] on H binding to surface-associated 
C3b. The binding sites on C3b for H have been analyzed by 
synthetic peptides and mAb, and at least two segments of C3b 
(residues 1187 1249 and 727-768) have been found to be in- 
volved in binding of C3b to H [20,21]. This fits well with the 
pattern of two distinct interaction sites between H and SRBC- 
C3b as suggested in the present paper. In contrast, some stud- 
ies have suggested that H has only one binding site for C3b 
[34,38], but these studies did not address possible differences 
in H binding to fluid-phase, activator-bound and non-activa- 
tor-bound C3b. It is possible that the putative second binding 
site on H for C3b is involved primarily during binding of H to 
non-activator-bound C3b. Therefore, these results may not 
necessarily be incompatible with those of the present study. 
In conclusion, our study has shown that (1) there are at 
least two binding sites on H for a surface-C3b complex, and 
(2) all anti-H mAb can enhance H binding to surface-asso- 
ciated C3b by forming H dimers at equimolar concentrations. 
Multiple interactions between C3b and H could thus provide 
flexibility for the alternative complement pathway to discrimi- 
nate between activators and non-activators. 
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